Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DULERA vs ADVAIR DISKUS
Head-to-head clinical comparison of therapeutic indices and safety profiles.
DULERA is a combination of formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), and mometasone furoate, a corticosteroid. Formoterol acts by relaxing bronchial smooth muscle via beta2-receptor activation. Mometasone furoate reduces inflammation in the lungs by inhibiting inflammatory mediators and suppressing immune responses.
Treatment of asthma in patients 12 years and older (FDA approved),Maintenance treatment of asthma (FDA),Prevention of exercise-induced bronchospasm (off-label use)
Inhalation: 2 inhalations twice daily (morning and evening). Each inhalation delivers mometasone furoate 100/200 mcg and formoterol fumarate 5 mcg.
Formoterol: terminal half-life 10-14 hours (supports twice-daily dosing); Mometasone: terminal half-life 13.8 hours (range 10-20 hours) after inhalation.
No specific dose adjustment required for renal impairment based on GFR.
LABA increase the risk of asthma-related death. When used without an inhaled corticosteroid, LABA are contraindicated in asthma. DULERA should only be used in patients not adequately controlled on a long-term asthma controller medication or whose disease severity warrants initiation of both an inhaled corticosteroid and LABA.
DULERA (mometasone furoate + formoterol fumarate) is classified as FDA Pregnancy Category C. No adequate human studies exist. In animal studies, inhaled corticosteroids at high doses caused teratogenic effects (cleft palate, delayed ossification). Formoterol showed no teratogenicity in rats at 16x MRHD, but beta-agonists may cause uterine relaxation and premature labor. Risk is likely low at therapeutic doses, but benefits must outweigh potential risks. First trimester: theoretical risk of malformations. Second/third trimester: possible fetal growth restriction and adrenal suppression with chronic corticosteroid use.
DULERA is a fixed-dose combination of mometasone furoate (an inhaled corticosteroid) and formoterol fumarate (a long-acting beta2-agonist). It is indicated for the maintenance treatment of asthma in patients aged 5 years and older, not for acute bronchospasm. Post-administration rinse mouth to prevent oral candidiasis. Do not use as rescue therapy; separate doses by 12 hours. Monitor for paradoxical bronchospasm and signs of adrenal insufficiency when switching from systemic corticosteroids. Formoterol may increase risk of asthma-related death; use lowest effective dose.
No interactions on record
No interactions on record
DULERA and ADVAIR DISKUS are distinct pharmacological agents. DULERA belongs to the Corticosteroid/Beta2-Agonist Combination class and is primarily used for Treatment of asthma in patients 12 years and older (FDA approved)Maintenance treatment of asthma (FDA)Prevention of exercise-induced bronchospasm (off-label use). ADVAIR DISKUS belongs to the indicated class and is primarily used for specified clinical guidelines. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. DULERA carries a safety status of Category C, whereas ADVAIR DISKUS safety is classified as Pending. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Mometasone furoate is extensively metabolized via CYP3A4 to multiple metabolites. Formoterol is primarily metabolized by direct glucuronidation and O-demethylation via CYP2D6 and CYP2C19, but CYP3A4 and CYP2C9 also contribute.
Formoterol: 10-15% renal as unchanged drug and metabolites, remainder hepatically cleared; Mometasone: >99% biliary/fecal as metabolites, <1% renal unchanged.
Formoterol: 61-64% bound to albumin; Mometasone: 98-99% bound to albumin and alpha-1-acid glycoprotein.
Formoterol: 3.4-4.5 L/kg; Mometasone: 332-580 L (not corrected for weight; corresponds to extensive tissue distribution).
Inhalation: Formoterol systemic bioavailability ~10-18%; Mometasone systemic bioavailability <1% due to extensive first-pass metabolism and low lung absorption.
Contraindicated in severe hepatic impairment (Child-Pugh C). For moderate impairment (Child-Pugh B), use with caution; no specific dose adjustment defined, but monitor for systemic effects.
Approved for children 12 years and older: Same as adult dose. For children <12 years, safety and efficacy not established.
No specific dose adjustment. Use lowest effective dose due to potential for increased sensitivity and comorbidities.
No significant food interactions reported. Avoid known dietary asthma triggers (e.g., sulfites, histamine-rich foods) as they may exacerbate underlying condition.
Mometasone furoate and formoterol are excreted in human milk in trace amounts; M/P ratio not available. Systemic exposure to infant is low via inhalation. Discontinue nursing or drug based on importance. Caution in preterm infants due to potential beta-agonist effects.
No standard dose adjustments recommended for DULERA in pregnancy. However, asthma severity may change; dose titration to achieve control is essential. Increased clearance of corticosteroids in pregnancy may require higher doses of inhaled corticosteroid component. Formoterol pharmacokinetics minimally changed. Max recommended doses: mometasone 800 mcg/day, formoterol 48 mcg/day. Postpartum dose reduction may be needed to avoid excessive corticosteroid exposure.
Use exactly as prescribed; do not exceed 2 inhalations twice daily.,Rinse your mouth with water after each use to reduce risk of fungal infection.,Do not use DULERA for sudden asthma symptoms; have a rescue inhaler available.,Continue taking other asthma medications unless instructed otherwise.,Seek medical help if symptoms worsen or you need more rescue inhaler than usual.,Avoid foods or drinks that trigger your asthma; no general food interactions.,Inform your doctor about all medications, especially beta-blockers and diuretics.,Store at room temperature, away from heat and open flames; do not puncture canister.